ARTL logo

Artelo Biosciences, Inc.

ARTL
Healthcare|Biotechnology|US
$1.91
-0.20 (-9.69%)
Tangible Book / Share
$9.82
Cash / Share
$13.93
Next Earnings Report
Nov 17, 2026
EPS est. -$7.02
Financing Filings (last 12 months)
11
Shelf registrations / offering prospectuses — latest May 26, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain
Oct 29, 2026 · GlobeNewsWire
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
Oct 26, 2026 · GlobeNewsWire
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
Oct 7, 2026 · GlobeNewsWire
Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings
Sep 23, 2026 · GlobeNewsWire
Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity
Sep 16, 2026 · GlobeNewsWire
Artelo Biosciences Announces Reverse Stock Split
Aug 27, 2026 · GlobeNewsWire
Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13
Aug 20, 2026 · GlobeNewsWire
Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies
Aug 17, 2026 · GlobeNewsWire
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Aug 13, 2026 · GlobeNewsWire

SEC Filings (105)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 9, 20268-KMaterial eventDocumentIndex
Aug 27, 20268-KMaterial eventDocumentIndex
Aug 20, 202610-Q/AQuarterly reportDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 202610-QQuarterly reportDocumentIndex
Jul 17, 20268-KMaterial eventDocumentIndex
Jul 16, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jul 16, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jul 2, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jun 22, 2026PRER14ADocumentIndex
Jun 5, 2026ARSAnnual report to holdersDocumentIndex
Jun 5, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jun 5, 2026DEF 14AProxy / shareholder voteDocumentIndex
May 27, 20268-KMaterial eventDocumentIndex
May 26, 2026PRE 14AProxy / shareholder voteDocumentIndex
May 26, 2026424B5Offering prospectusDocumentIndex
May 19, 2026EFFECTDocumentIndex
May 18, 2026424B5Offering prospectusDocumentIndex
May 15, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 14, 202610-QQuarterly reportDocumentIndex
May 14, 2026S-3/AShelf registrationDocumentIndex
May 4, 2026S-3Shelf registrationDocumentIndex
Apr 16, 2026424B3Offering prospectusDocumentIndex
Apr 15, 2026EFFECTDocumentIndex
Apr 7, 2026S-1IPO / offering registrationDocumentIndex
Apr 7, 20268-KMaterial eventDocumentIndex
Apr 6, 2026DDocumentIndex
Apr 3, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 30, 2026EFFECTDocumentIndex
Mar 30, 20268-KMaterial eventDocumentIndex
Mar 27, 2026DDocumentIndex
Mar 27, 2026DDocumentIndex
Mar 27, 2026DDocumentIndex
Mar 27, 2026RWDocumentIndex
Mar 26, 20268-KMaterial eventDocumentIndex
Mar 25, 2026EFFECTDocumentIndex
Mar 24, 2026S-1IPO / offering registrationDocumentIndex
Mar 24, 2026S-1/AIPO / offering registrationDocumentIndex